Abnormalities, Multiple: Clinical Trials

8 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 active not recruiting. 8 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Active not recruiting 8
Phase 22Active not recruiting 2

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
obudanersen, Placebo - Angelman Syndrome
Phase 3Active not recruitingIonis Pharmaceuticals, Inc.1562025-06-102026-11-19
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
tVNS, intermittent stimulation, tVNS, continuous stimulation - Prader-Willi Syndrome
Phase 3Active not recruitingFoundation for Prader-Willi Research1022024-01-082026-04-06
Oral N-acetylcysteine for Retinitis Pigmentosa
N-acetylcysteine, Placebo - Retinitis Pigmentosa
Phase 3Active not recruitingJohns Hopkins University4852023-10-112026-06-15
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
CAM2029, Placebo - Polycystic Liver Disease
Phase 2 / Phase 3Active not recruitingCamurus AB712022-06-282026-06-01
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome
Phase 2 / Phase 3Active not recruitingQuoin Pharmaceuticals302022-06-232026-03-16
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Odevixibat - Alagille Syndrome
Phase 3Active not recruitingAlbireo, an Ipsen Company622021-09-032026-10-23
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3Active not recruitingNational Cancer Institute (NCI)67202019-07-032026-11-12
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome
Phase 3Active not recruitingChildren's Oncology Group2802015-12-232026-08-19

Narrower conditions

Down Syndrome (2)  ·  Alagille Syndrome (1)  ·  Angelman Syndrome (1)  ·  Burkitt Lymphoma (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Netherton Syndrome (1)  ·  Polycystic Kidney, Autosomal Dominant (1)  ·  Polycystic liver disease (1)  ·  Prader-Willi Syndrome (1)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Retinitis Pigmentosa (1)  ·  Usher Syndromes (1)

Broader conditions

Congenital Abnormalities (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Genetic Diseases, Inborn (8)  ·  Nervous System Diseases (5)  ·  Chromosome Disorders (4)  ·  Neurologic Manifestations (4)  ·  Intellectual Disability (3)  ·  Neurobehavioral Manifestations (3)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Imprinting Disorders (2)  ·  Leukemia (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)

Interventions

Asparaginase (2)  ·  Cytarabine (2)  ·  Thioguanine (2)  ·  asparaginase erwinia chrysanthemi recombinant (2)  ·  Acetylcysteine (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Daunorubicin (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Leucovorin (1)  ·  Leyk (1)  ·  Mercaptopurine (1)  ·  Methotrexate (1)

Sponsors

Albireo, an Ipsen Company (1)  ·  Camurus AB (1)  ·  Children's Oncology Group (1)  ·  Foundation for Prader-Willi Research (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Johns Hopkins University (1)  ·  National Cancer Institute (NCI) (1)  ·  Quoin Pharmaceuticals (1)

Countries

United States (8)  ·  Canada (4)  ·  Germany (4)  ·  Australia (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Poland (2)  ·  Puerto Rico (2)  ·  Austria (1)  ·  France (1)  ·  Israel (1)  ·  Japan (1)

Top investigators

Deepan Singh, MD (1)  ·  Jason N Berman (1)  ·  Joost Drenth, MD (1)  ·  Peter A Campochiaro, MD (1)  ·  Sumit Gupta (1)  ·  Theresa Strong, PhD (1)  ·  Tony Andrasfay (1)  ·  Xiangrong Kong (1)

Results publications

PMID 33844429, PMID 39356039, PMID 39651791, PMID 41124669, PMID 41282901, PMID 42635483

NIH funding

U10CA180886 (2), 1UG1EY033293 (1), 2023 (1)